Antenatal sickle cell disease haemoglobinopathy screening

Responding to

Antenatal haemoglobinopathy screening
by Judy Shakespeare
BMJ 341:doi:10.1136/bmj.c5243 (Published 18 October 2010) www.bbj.com

Rapid Response http://www.bmj.com/content/341/bmj.c5243/reply#bmj_el_243447

October 25 2010 by

Felix ID Konotey-Ahulu, Kwegyir Aggrey Distinguished Professor of Human Genetics University of Cape Coast , Ghana  and Consultant Physician Genetic Counsellor in Sickle&Other Haemoglobinopathies 10 Harley St London W1G
The commissioned editorial [Reference 1] of Judy Shakespeare (18 October) is as comprehensive as the article [2] of Elizabeth Dormandy et al whose concerns the editorial underlined. My comments with references [3] on the Elizabeth Dormandy paper are therefore equally applicable to both articles, and will not largely be repeated here. But there are a couple of clarifications which readers would like to see made.  

CLARIFICATIONS NEEDED

What does the following mean? “Antenatal screening for sickle cell disease and thalassaemia is just the tip of a genetic iceberg and primary care needs to be prepared.” [1]. How can screening be the tip of an iceberg?
Nor is the following easily comprehensible: “In the United Kingdom , about 250,000 people are healthy carriers of sickle cell gene variants and 12,500 have the disease ..”

 What are healthy carriers of sickle cell gene variants? Does the author mean beta-globin gene variants? If as Judy Anderson states, her fellow general practitioners need to “raise their awareness and skills” to educate their patients are they likely to understand what “sickle cell gene variant carrier” means?

GHANAIAN BASIC TERMINOLOGY ACCEPTABLE TO EVEN ILLITERATES

Will UK General Practitioners countenance the terminology I use to instruct Ghanaian illiterates and fellow health staff with the message of sickle cell disease inheritance? For decades I have told them that all Ghanaians are divided into 3 broad phenotypes, using my own parents and their children [Reference 4] as examples: (i) ACHEACHE (those who have inherited an ACHE gene from both parents and therefore ache in the cold rainy season with sickle cell disease, like 3 of my parents’ 11 children) (ii) NORMNORM (no cold season rheumatism, like 4 of my parents’ children, having inherited no abnormal haemobglobin, and blood test shows no beta globin variant) (iii) NORMACHE (no cold season rheumatism, like the other healthy 4 of us but blood test shows one beta globin variant trait, like our parents). Every new patient of mine for several decades now has had Haemoglobin Electrophoresis done, confirming that 1 in 3 of West Africans is NORMACHE ie a Trait. In my experience, the assumption that identified NORMACHE x NORMACHE marriages will be queuing up to have prenatal diagnosis and selective abortion done when offered it is too presumptuous for the reasons already given in my earlier comments [Reference 3]. Many prefer genetic gambling, then stopping procreation after 1 or 2 children if they happen to avoid ACHEACHE phenotype. If a sickle cell disease offspring arrives, they do not panic because they know many adult ACHEACHE Achievers. [3]

SICKLE CELL DISEASE HAEMOGLOBINOPATHY IS DIFFERENT

 
Sickle cell anaemia, a qualitative molecular pathology ‘SS phenotype’, and beta thalassaemia major a quantitative molecular pathology are both, as Judy Shakespeare correctly points out [1] homozygous recessive, but their public health handling must be entirely different [Reference 3]. No where in the world is beta-thalassaemia minor, the heterozygote, 33.3% of the healthy population, whereas if one phenotypes West Africans anywhere in the world well above 35% of us will be NORMACHE, ie traits of abnormal haemoglobins (AC or AS), and we do not know it until we are investigated by Hb electrophoresis. Helping Ghanaians and Nigerians to make informed decisions in procreation does not lie in prenatal diagnosis and selective abortion as appears to be the case in Cyprus , but does lie in Genetic Counselling with Voluntary Family Size Limitation. [References 4 & 5]. And, take it from me, that works!

Felix I D Konotey-Ahulu MD(Lond) FRCP DTMH ORDER OF THE VOLTA ( GHANA )
Dr Kwegyir Aggrey Distinguished Professor of Human Genetics University of Cape Coast , Ghana and Consultant Physician Genetic Counsellor in Sickle and Other Haemoglobinopathies. [felix@konotey-ahulu.com]

 
Conflict of interest: My parents who were traits for abnormal haemoglobins, had 11children 3 of whom had sickle cell disease, 4 are traits and 4 have no beta globin gene variant.

1 Shakespeare Judy. Antenatal haemoglobinopathy screening. BMJ 2010; 341: c5243 (Editorial 18 October)

2 Dormandy Elizabeth, Gulliford Martin, Bryan Stirling, Roberts Tracy E, Calnan Michael, Atkin Karl, Karnon Jonathan, Logan Jane, Kavalier Fred, Harris Hilary J, Johnston TraceyA, Anionwu Elizabeth N, Tsianakas Vicki, Jones Patricia, Marteau Theresa M. Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial. BMJ 341:doi:10.1136/bmj.c5132 (5 October 2010)

3 Konotey-Ahulu FID. Antenatal screening for sickle cell disease and beta-thalassaemia. http://www.bmj.com/content/341/bmj.c5132/reply#bmj_el_242914 BMJ Rapid response. 12 October 2010

4 Konotey-Ahulu FID. Sickle cell disease in successive Ghanaian generations for 3 Centuries. http://www.konotey-ahulu.com/images/generation.jpg 

In The Human Genome Diversity Project: Cogitations of An African Native. Politics and the Life Sciences (PLS) 1999, Vol 18: No 2, pp 317-322. [Invited Commentary on Professor David Resnik’s article: The Human Genome Diversity Project: Ethical Problems and Solutions] PMID: 12561789 [PubMed – indexed for MEDLINE]

5 Konotey-Ahulu FID. Sickle Cell Disease: The Case for Family Planning. Accra . ASTAB Books, Ltd 1973

Competing interests: My parents who were traits for abnormal haemoglobins, had 11 children 3 of whom had sickle cell disease, 4 are traits and 4 have no beta globin gene variant.

The politics (and economics) of pain relief in the West and Third World

Feature: Pain control : The politics of pain
• Tatum Anderson
BMJ 341:doi:10.1136/bmj.c3800 (Published 11 August 2010) – www.bmj.com

The politics (and economics) of pain relief in the West and Third World
o Felix ID Konotey-Ahulu, Kwegyir Aggrey Distinguished Professor of Human Genetics University of Cape Coast Ghana
Consultant Physician Genetic Counsellor in Sickle/Other Haemoglobinopathies 10 Harley St London W1G
The politics (and economics) of pain relief in the West and Third World
Tatum Anderson (14 Aug, p 328) wished pain relievers elsewhere could imitate the “Western world” [1]. His concern needs to be put into perspective. Referring to Armenia he quotes Dr Karfeptyan as saying “Finances remain a problem” [1]. Yes, Health Ministers decide which imported drugs have priority over others.

WHO RECOMMENDATIONS
Tatum Anderson mentions WHO recommendations on pain relief, but WHO
More…
The politics (and economics) of pain relief in the West and Third World
Tatum Anderson (14 Aug, p 328) wished pain relievers elsewhere could imitate the “Western world” [1]. His concern needs to be put into perspective. Referring to Armenia he quotes Dr Karfeptyan as saying “Finances remain a problem” [1]. Yes, Health Ministers decide which imported drugs have priority over others.

WHO RECOMMENDATIONS
Tatum Anderson mentions WHO recommendations on pain relief, but WHO guidelines are not accompanied by money. Useful on paper, they can nevertheless be ignored. Exactly 38 years ago WHO convened some of us to produce an 83-page Technical Report on how to tackle the problem of Sickle Cell Disease. [2]. It was ignored. .
But WHO makes other recommendations which do not rely on foreign aid. WHO knows Traditional Medicine which costs a fraction of what imported drugs cost is widely used [3 4], and aims to “support and integrate traditional medicine into national health systems” [4]. True, some Africans cannot afford imported opiates but “85% of Nigerians use and consult traditional medicine for health care” [5]. Indeed, the pain of my own circumcision when a little boy was managed by a Krobo traditional healer who also “knew about haemostasis” [6]. Neither the ground haemostatic herbs nor the pain killing tincture came from abroad. Did the oral morphine that the Ugandans in Tatum Anderson’s article were using come from abroad, or did they get it from their traditional healers as WHO would have approved of?

WESTERN NATIONAL INTERESTS FIRST BEFORE ANYTHING ELSE
Tatum Anderson writes as if “The Western world” speaks with one voice. Take his comment: “Also, many patients with conditions, such as sickle cell anaemia, …require relief but do not get it” [1] The UK uses Diamorphine for sickle cell crisis patients [7 8], while “heroin has no accepted use in the United States” [9, page 168]. Do these two countries not belong to “The West” and yet do they not differ in their use of this particular opiate? That national interests have more to do with choice of drugs in their Pharmacopoeia is shown by UK’s reaction to Professor Elisabeth Goodman’s finding in the USA [10] that the use in painful crises of Ketorolac was as efficient as morphine but without the latter’s respiratory depression: “Ketorolac has no product licence in the UK for this indication” [11]. Professor Graham Serjeant has stated: “In Jamaican experience morphia or its derivatives are rarely used or necessary” [12, page 204]. I agree [3].

GHANAIAN SICKLE CELL DISEASE ACHIEVERS
On 19 July 2010 The Third International Conference On The Achievements of Sickle Cell Disease Patients [14] was held in Accra, followed on 20-23 July by The First Global Congress On Sickle Cell Disease to mark the 100th anniversary of the first clinical description of Sickle Cell Disease. The Conference had sickle cell anaemia adults in their 7th decade tell us how they managed to achieve great things [14 15]. One known “SS” man with a PhD, who had never in his 63 years been transfused though Hb level was never above 8.8 g/dL and who had never been prescribed Hydroxyurea, astonished delegates when he announced “I do not know when I last took a pain killer for my sickle cell anaemia. Drink plenty of water, avoid malaria, and have a positive attitude to life” [14, page 15].

NATIONAL ENQUIRY INTO PATIENTS OUTCOME AND DEATH (NCEPOD)
The NCEPOD report [7 8] concludes that during 2 years “Nine out of the 19 patients with sickle cell disease who had pain on admission and who then died had been given excessive doses of opiods” [8], and this continues to happen [16 17] in spite of UK’s National Institute of Clinical Excellence (NICE) [18 19]. Is post narcotic administration death (pnad) the kind of relief that Tatum Anderson’s “West” is seeking for our patients, many of whom have become bread winners when their hereditary condition is managed properly? [20 21]

WHAT THE THIRD WORLD CAN AND MUST LEARN FROM THE WEST
There is plenty though The Third World can learn from the West, not least of which is ‘Discipline’ in personal and national affairs. We must learn that every privilege demands some responsibility. Why should it be implied [1] that Bill and Melinda Gates could supply us with free morphine? Why should we Africans expect help to come from outside when we refused to learn lessons like Singapore had done?
Next, we Africans need discipline against corruption. I described how a Lebanese, an Italian, plus a Ghanaian conspired and supplied the Ministry of Health in Accra with Ampicillin capsules stuffed with chalk and cassava powder as “500 mg Ampicillin” [22]. The then Commissioner of Health to whom I reported this, and who began to probe the racket was promptly removed from his post [22]. True, the Italian crook came from the “West” but, generally speaking, “The West” is ready to show us the proper means and ways to deal with situations like that [22]. Our envy of “The West” knows no bounds when we read of their ability to prosecute a French President, discipline a German Chancellor, investigate an Israeli Prime Minister, dismiss a Japanese Minister, and remove a sitting American President for “simply lying”. Twice in less than 3 years the BMJ has published articles on pain relief for Africans [1 23]. Can we also have articles showing how “The West” could help us prevent a Minister of Health from being removed for probing crooks in the pharmaceutical industry, and how we should not expect Bill and Melinda Gates to give us free antimalarial drugs when we have not covered open drains in our cities like Singapore and Trinidad have done? [24].
Felix I D Konotey-Ahulu MD(Lond) FRCP DTMH Dr Kwegyir Aggrey Distinguished Professor of Human Genetics University of Cape Coast, Ghana and Consultant Physician Genetic Counsellor in Sickle and Other Haemoglobinopathies, 10 Harley Street, London W1G 9PF felix@konotey-ahulu.com

1 Anderson Tatum. The politics of pain. Brit Med J 2010; 341: c3800 http:// www.bmj.com/cgi/content/full/341/aug11_2/c3800
2 Boyo AE, Cabannes R, Conley CL, Lehmann H, Luzzatto L, Milner PF, Ringelhann B, Weatherall DJ, Barrai I, Konotey-Ahulu FID, Motulsky AG. Scientific Group on Treatment of Haemoglobinopathies and Allied Disorders. (Technical Report) 1972; 509 – 83 pages.
3 WHO. Traditional Medicine Strategy 2002-2005. Geneva: WHO 2002
4 WHO. Traditional Medicine. Fact Sheet No; 134. http://www.who.int/mediacentre/factsheets/fs134;en
5 Adelaja Abiose. Nigeria boosts research into traditional medicine. Sci Dev Net Dec 6 2006 http://www.scidev.net/en/news/nigeria- boosts-research-into-traditional-medicine.html
6 Konotey-Ahulu FID. Male circumcision and alleged protection against AIDS. http://www.bmj.com/cgi/eletters/335/7631/1206# BMJ 11 Dec 2007 Rapid Response
7 NCEPOD (National Confidential Enquiry into Patient Outcome and Death). Sickle: A Sickle Crisis? (2008) [Sebastian Lucas (Clinical Co- ordinator), David Mason (Clinical Co-ordinator), M Mason (Chief Executive), D Weyman (Research), Tom Treasurer (Chairman) info@ncepod.org
8 Mayor Susan. Enquiry shows poor care for patients with sickle cell disease. BMJ 2008; 336: 1152.
9 Ballas S K. Sickle Cell Pain. IASP Press. Seattle, USA.
10 Goodman Elisabeth. Use of ketorolac in sickle cell disease and vaso-occlusive crisis. Lancet 1991; 338: 641-42.
11 Liesner RJ, Vandenberghe EA, Davies SC. Analgesics in sickle cell disease. Lancet 1993; 341: 188.
12 Serjeant GR. Sickle Cell Disease. Oxford. Oxford University Press, 1985, page 204.
13 Konotey-Ahulu FID. Morphine for painful crises in sickle cell disease. BMJ 1991; 302: 1604.
14 Amanor-Boadu Dorothy, Bruce-Tagoe Alexander, Konotey-Ahulu Felix. The Third International Conference On The Achievements Of Sickle Cell Disease (ACHEACHE) Patients. Accra – 19th July 2010. Adeko Ltd, Accra, Ghana. ISBN: 978-9988-1-3927-8.
15 The Second International Conference On The Achievements Of Sickle Cell Disease Patients, Accra 19th July 1995.
16 Dyer Clare. Inquest begins into deaths after concerns about diamorphine levels. BMJ 2009; 338: b903 [7 March]
17 Konotey-Ahulu FID. Inquest into diamorphine deaths; Does NCEPOD sickle cell patients report warrant a similar inquest? BMJ Rapid response 7 March 2010. http://www.bmj.com/cgi/eletters/338/mar03_3/b903#210208
18 Konotey-Ahulu FID. Poor care for sickle cell disease patients: This wake up call is overdue. http://www.bmj.com/cgi/elettres/336/7654/1152-a#196224 BMJ Rapid response 29 May 2008.
19 Konotey-Ahulu FID. Current “hit and miss” care provision for sickle cell disease patients in the UK. BMJ Rapid Response 22 July 2008 http://www.bmj.com/cgi/eletters/337/jul11_2/a771#199135
20 Serjeant GR. The case for dedicated sickle cell centres. BMJ 2007; 334: 477 (3 March)
21 Konotey-Ahulu FID. Dedicated sickle cell centres. BMJ Rapid response March 20 http://www.bmj.com/cgi/eletters/334/7591/477#162678
22 Konotey-Ahulu FID. Who should best pharmacovigilate in developing countries? 14 September 2007 BMJ Rapid Response to Editorial http://www.bmj.com/cgi/eletters/335/7618/462#167455
23 Logie Dorothy, Leng Mhoira. Africans die in pain because of fears of opiate addiction. BMJ 2007; 335: 685 http://www.bmj.com/cgi/content/full/335/7622/685 October 6 2007.
24 Konotey-Ahulu FID. Fighting Malaria: Isn’t the best approach through Environmental Hygiene and Public Health? BMJ Rapid Response April 26 2009 http://www.bmj.com/cgi/eletters/338/apr20_2/b1627#212782
Competing interests: None declared

Third International Conference on the Achievements of Sickle Cell Disease Patients

The Third International Conference on the Achievements of Sickle Cell Disease Patients will take place at the Accra International Conference Centre on Monday 19th July, the day before the First World Congress On Sickle Cell Disease begins at the same venue. Attendance is free. Contact Co-Chairs Ms Dorothy Amanor-Boadu (elitens@yahoo.co.uk), Professor Alex Bruce-Tagoe (alexbt_2000@yahoo.com) and Professor Felix Konotey-Ahulu (felix@konotey-ahulu.com), and also the Local Chair for the World Congress Dr Ivy Ekem (ekem_ivy@hotmail.com)

TONIC SOLFA IS THE FOUNDATION OF TONAL LINGUISTICS: University of Cape Coast 40th Congregation Occasional Lecture Series, Ghana 12 October 2009

My Mother Tongue, Krobo/Dangme-Gã of south-east Ghana was first written by the Swiss-German Basel Missionaries who not only translated the Bible for us, but also wrote hymns for us with the help of local experts born in the Gold Coast. They did a remarkable job, but as the Ghanaian vowel imparts no less than 6 meanings to any consonant my parents and grandparents had to look at the context in which a written word appeared before pronouncing the word correctly. For example, the word written ‘ta’ can mean chew, war, giant ant, to fish out of a bowl, palm tree, or narrate in Krobo/Dangme. My parents were adept at quickly scanning a sentence mentally before deciding what the ‘ta’ they had just read stood for.
To read more click here to view the PDF document.

Origin of the Genetic Code is suprascientific

Origin of the Genetic Code is suprascientific
http://jrsm.rsmjournals.com.newproxy.rsm.ac.uk/cgi/eletters/103/2/43 Journal of Royal Society of Medicine March 15 2010
Response: The disappointments of the double helix: a master theory
Origin of the genetic code is suprascientific
The title of Dr James Le Fanu’s magnificent article suggests inadvertently that, with all the advances in genomic research, our inability to have “a mind capable of understanding the origins of the universe” [1] is to be blamed on the double helix when he could justifiably have pointed his finger at ourselves.
Discoverer of the ‘Double Helix’, Nobel Laureate Francis Crick, confessed his inability to explain “the origin of the genetic code” [2]. I discovered the reason why from Professor Sir Peter Medawar FRS OM, another Nobel Laureate, who taught that questions like origins not only go “beyond the explanatory confidence of science” [3 (p. xiii)] but also that “science cannot answer these ultimate questions and no conceivable advance of science could empower it to do so” [3 (p. 59)].
It is beginning to dawn on some of the world’s brightest scientists that Medawar is quite right, and that DNA, with its genetic code, belongs to the lowest rung (statistics) of information-transmission whose other rungs, in ascending order, capable of sending a message and producing results are syntax, semantics, pragmatics, and apobetics [4]. Useful messages do not arise anyhow. The first question I ask when I receive useful information is not “How was this information sent?” but “Who sent this?”
Until we begin to accept Medawar’s humbling limitation of the “explanatory confidence of science” [3] and admit that the origin of the universe and of DNA information programming in particular, is in the realm of the “suprascientific” [5] we shall continue (as we do at present) to be “whistling in the dark to keep our scientific courage up” [5].
Felix ID Konotey-Ahulu, Kwegyir Aggrey Distinguished Professor of Human Genetics, University of Cape Coast, Ghana and Consultant
Physician Genetic Counsellor, Sickle & Other Haemoglobinopathies 10 Harley St., London W1G 9PF
E-mail: felix@konotey-ahulu.com
Competing interests: None declared
References
1 Le Fanu J. The disappointments of the double helix: a master theory. J R Soc Med 2010; 103: 43-45. DOI.101258/jrsm.2009.09k077 February 2010
2 Crick FHC. The origin of the genetic code. J Mol. Biology 1968: 38: 367-379.
3 Medawar P. The Limits of Science. Oxford. Oxford University Press, 1985 pp xiii & 59.
4 Gitt Werner. In the beginning was Information. Christliche Literatur-Verbretung e.V.
Postfach 110135.33661 Bielefeld, Germany, 2001.
5 Konotey-Ahulu FID. The suprascientific in clinical medicine – a challenge for
Professor Know-All http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1121901
Brit Med J. 2001; 323: 1452-1453

Are patients with G6PD Deficiency to avoid eating prawns?

Are patients with G6PD Deficiency to avoid eating prawns that have been farmed?
In his very informative editorial (March 4) Geoff Scott says “Chloramphenicol is also used in certain practices in agriculture, such as the farming of prawns” [Reference 1]. Should I, therefore, mention to my Ghanaian patients one in five males (hemizygotes) of whom were born with G6PD Deficiency [References 2-4] that eating prawns that have been farmed could lead to what Geoff Scott calls “dangers of unwanted effects” [Reference 1]?
That would increase my list [See Reference 5] from 20 to 21 of how to recognize effects of Glucose-6 Phosphate Dehydrogenase deficiency in Ghanaian hemizygotes, female heterozygotes, and the homozygotes that constitute 1 in 16 of all females at home in Ghana and in the diaspora [2].
Felix ID Konotey-Ahulu MD FRCP DTMH
Kwegryir Aggrey Disitnguished Professor of Human Genetics, University of Cape Coast, Ghana and
Consultant Physician Genetic Counsellor in Sickle and other Haemoglobinopathies, 10 Harley Street, London W1G 9PF
Email: felix@konotey-ahulu.com
Conflict of interest: None declared
1 Scott Geoff. Over the counter chloramphenicol eye drops. BMJ 2010; 340 c1016
http://www.bmj.com/cgi/content/full/340/feb26_1/c1016
2 Owusu SK. Absence of glucose-6 phosphate dehydrogenase in red cells of an African. BMJ 1972; 4: 25-26
3 Owusu SK, Foli AK, Konotey-Ahulu FID, Janosi Marianne. Frequency of glucose-6 phosphate dehydrogenase deficiency in typhoid fever in Ghana. Lancet 1972; 1: 320
4 Owusu SK. Glucose-6 phosphate dehydrogenase (G6PD) deficiency in causation of disease in Ghana. Ghana Medical Journal 1974; 13: 168-170
5 Konotey-Ahulu FID. G-6PD Deficiency in Ghanaians: How to recognize it. http://blog.konotey- ahulu.com/blog/_archives/2008/1/16/3468557.html Jan 2008.
Competing interests: None declared

Sickle Cell Disease Patients dying from Opiates: Why no co-operation among doctors?

I am very concerned at what appears to be inadequate cooperation among medical practitioners who I had always assumed worked in harmony to improve the quality of patients' lives and save lives that can be saved.

If I have understood correctly, in the first few years of training, medical practitioners learn that opiates, notably morphine and heroin (Diamorphine) have an effect on the cerebellum and deprive the system of oxygen. It is therefore advised that as there are numerous alternatives available, they should absolutely not be used as a pain killer unless a patient is terminally ill, very near to death and in excruciating pain which no other pain killer can relieve.

Do I understood that those physicians who continue to prescribe these drugs have forgotten what they have been taught or choose to ignore the fact even when reminded? What is happening to the life-saving dictum of the profession where some doctors are concerned?

In November 2008, I went to an emergency room at a clinic in Geneva , Switzerland where I live, with a blasting chest pain. My condition was soon further complicated by excruciating pain in my left hip.

My new lease on life is because medical practitioners did not contest my refusal of a morphine injection to relieve excruciating pain in my chest and hip. The physicians attending to me would have loved to relieve me of the pain with morphine but respected the knowledge, however little, and understanding I had of the way in which opiates affect the brain and therefore the entire system. They deprive the system of oxygen which is desperately vital in my condition, Sickle Cell Disease.

I had double pneumonia and pleurisy. The infection had provoked a sickle cell crisis. Before they had realised the extent of my illness, the fact that I was a sickle cell disease (SC) patient was enough for the physicians attending me NOT to insist on administering morphine. One of them said that my pain had reached the maximum the human body could endure.

Unfortunately, some physicians force patients to have morphine. Whether one is a sickle cell patient or not, opiates in my opinion, are not to be recommended.

I am allergic to aspirin and therefore must avoid no fewer than 34 prescription and over-the-counter medications, including Ketorolac (Toradol) which is very effective in relieving excruciating pain.

There are so many misconceptions about sickle cell disease that I took the book “The Sickle Cell Disease Patient” by F I D Konotey-Ahulu to the clinic and my daughter handed it to the physician attending to me. My three adult children are well informed about my health issues and therefore telephoned Professor Felix Konotey-Ahulu abroad for guidance. My physicians were very happy to consult with him by telephone. He confirmed that I was right to refuse the administration of morphine and together they co-operated in making me comfortable and well again.

I was fortunate enough not to need a blood transfusion (neither total nor partial).

It may help medical practitioners to know that over the 12-days that I was in the clinic in Geneva, medication I was given was Dafalgan, Valium, Tramal, Perfalgan, Rocephine, Klacid, Franxiperine, Nexium and Tavanic and Motilium lingual. I also had Oxygen, NaCl and Glucose. No Morphine or Diamorphine!

On leaving the clinic in Geneva , I went to a convalescence clinic. A physician at the convalescence clinic asked why I had refused morphine. When I explained why, a colleague of his pointed to the back of his head, reminding him of the effect opiates have on the brain.

I am privileged to interact with physicians for whom I have the highest respect, one reason being because they take due consideration of what I, their patient, say and they listen to my children as well. The physicians are humble enough to take hold of a receiver and cooperate with another physician abroad in saving a life. They admit to me that they have been very happy to deepen their knowledge and would be pleased to learn more.

Had I been given the morphine or any other opiate, because of my double pneumonia with sickle cell disease, I would not be writing today, pleading with physicians to have compassion on patients who sometimes suffer very uncomfortable psychological problems (however temporary) as a result of having been given opiates and those who die as a result of having been given opiates.

The physicians who seem not to understand should try putting themselves in the position of families plunged into unbearable grief because of carelessness – a loved one was given opiates unnecessarily.

In spite of myself I begin to wonder whether Professor Felix Konotey- Ahulu's very practical and uncomplicated life-saving advice is being ignored by some medical practitioners because of his African origins. I believe his advice is based on what every medical practitioner learns at medical school.

Mawunu Chapman Nyaho
Geneva

Competing interests: None declared

Source : http://www.bmj.com/cgi/eletters/339/sep01_1/b3536#220670

UK drug related deaths are still rising: So where is NICE?

http://www.bmj.com/cgi/eletters/339/sep01_1/b3536#219836

Susan Mayor, 5 September, has done well to draw attention to 2 reports that reveal “the numbers of people dying because of poisoning from legal and illegal drugs are still increasing” [1] The first report said “Almost a third of the deaths where specific drugs were mentioned on the death certificate were related to heroin or morphine” [1, 2] The second report from St George’s University of London showed a 2.7% rise in the number of drug related deaths confirmed by inquest. Here too “Heroin and morphine accounted for most of these deaths” [3]. And these were the very drugs that the NCEPOD Report [4] found had produced deaths in sickle cell disease patients from overdose, and about which I continued to protest [5- 8].

HOW LONG WILL THIS CONTINUE FOR?

How long this situation is destined to continue is not clear. Writing to the Prime Minister and Health Ministers as I did, produced a response from Downing Street [6], but other ministers did not even bother to acknowledge my letters of concern. The United States of America has banned Diamorphine (Heroin) from all clinical practice [9], and that great country does not even have a National Institute of Health and Clinical Excellence (NICE). I would dearly want to know what percentage of the members of NICE are practicing Clinicians. Do they not know that Diamorphine suppresses respiration thus producing more in vivo sickling in sickle cell crisis [10, 11, 12]? Never mind how many UK Professors of Haematology approve of the practice, but do the Clinicians on NICE not know that it is this “legal” Diamorphine that (as Susan Mayor writes) is pushing up “the numbers of people dying because of poisoning from legal and illegal drugs” [1]?

IS MY PROTEST JUSTIFIED OR NOT?

But why do I continue protesting like this? ANSWER: First of all, I did not train in the bush somewhere in Africa. I was trained in London University’s Westminster Hospital School of Medicine by Physicians and Surgeons of King George VI and Queen Elisabeth II. My teachers taught me never to give Diamorphine or morphine to someone who could not breathe and whose red cells were bound to sickle further and clog up vital organs [13]. Secondly, I was second born of my parents’ 11 children 3 of whom had sickle cell disease, allowing me to know much about the disease before I went to university [14]. Thirdly, I was once in charge of the largest sickle cell disease clinic in the world, seeing personally hundreds of patients in sickle cell crisis [15, 16], salvaging many to grow up to use their brilliant non-sickling genes to achieve great things later in life, an experience which led me to begin writing about the sickle cell disease patient more than 44 years ago [17].

MY ADVICE TO NATIONAL INSTITUTE OF HEALTH AND CLINICAL EXCELLENCE

In the light of the above I make no apologies to take it upon myself to advise NICE to stop standing on the sidelines, and add to their many pronouncements one that forbids the “legal” use of Heroin (Diamorphine) for sickle cell disease patients. This, at least, was one thing NICE could learn from the USA [9].

GENETIC COUNSELLING AND VOLUNTARY FAMILY SIZE LIMITATION

The real answer for now, and the future, as I have been saying for decades is Genetic Counselling and Family Planning [18, 19] warning my fellow Africans that if they did not check themselves for a beta-globin gene variant (an ACHE gene) they might suddenly find themselves with a child born with an ACHEACHE phenotype (ACHE from father and ACHE from mother), like Sickle Cell Disease, and “the genetic burden on the National Health Service will go up and up” [20]. If born in the UK, the child could never escape Diamorphine treatment in sickle cell crisis. Was that really a prospect my country men and women would cherish?

Felix I D Konotey-Ahulu MD(Lond) FRCP DTMH Dr Kwegyir Aggrey Distinguished Professor of Human Genetics, University of Cape Coast, Ghana and Consultant Physician Genetic Counsellor in Sickle & Other Haemoglobinopathies, 10 Harley Street London W1G 9PF.

felix@konotey-ahulu.com

1 Mayor Susan. UK drug related deaths are still rising say two reports. http://www.bmj.com/cgi/content/full/339/sep01_1/b3536 BMJ 2009; 339: b3536

2 Deaths related to drug poisoning www.statistics.gov.uk/pdfdir/dgdths0809.pdf August 2009.

3 The St George’s Annual Report August 2009 www.sgul.ac.uk/about-st-georges/divisions/faculty-of-medicine-and- biomedical-sciences/mental-health/icdp/our-work-programmes/nationa/- programme-on-substance-abuse-deaths

4 NCEPOD (National Confidential Enquiry into Patient Outcome and Death). SICKLE: A Sickle Crisis? (2008) [Sebastian Lucas (Clinical Co- ordinator), David Mason (Clinical Co-ordinator), M. Mason (Chief Executive), D Weyman (Research), Tom Treasurer (Chairman)] info@ncepod.org

5 Konotey-Ahulu FID. Poor care for sickle cell disease patients: This wake up call is overdue BMJ Rapid Response May 28 2008 BMJ 2008; 336: 1152 http://www.bmj.com/cgi/eletters/336/7654/1152a#196224 to Susan Mayor “Enquiry shows poor care for patients with sickle cell disease” on National Confidential Enquiry into Patient Outcome and Death (NCEPOD) REPORT “SICKLE: A Sickle Crisis? (2008) info@ncepod.org

6 Konotey-Ahulu FID. Current “hit and miss” care provision for sickle cell disease patients in the UK. http://www.bmj.com/cgi/eletters/337/jul11_2/a771#199135 BMJ Rapid Response 22 July 2008

7 Konotey-Ahulu FID. Management of sickle cell disease versus management of the sickle cell disease patient. http://www.bmj.com/cgi/elettrs/337/sep08_1/a1397#202088 BMJ Rapid Response 17 September 2008

8 Konotey-Ahulu FID. Inquest into diamorphine deaths: Does NCEPOD sickle patients report warrant a similar inquest? BMJ Rapid Response March 7 2009 http://www.bmj.com/cgi/eletters/338/mar03_3/b903#210208

9 Ballas SK. Sickle Cell Pain. IASP Press. Seattle 1998.

10 . Konotey-Ahulu, FID. Morphine for painful crises in sickle cell disease. BMJ 1991, 302(6792): 1604. (June 29 1991) (Comment on Professor Chamberlain's recommendation of morphine in pregnancy in sickle cell disease – BMJ 1991; 302: 1327-30.) doi:10.1136/bmj.302.6792.1604-c http://www.bmj.com/cgi/reprint/302/6792/1604-c.pdf PMID: 1855060 PubMed- indexed for MEDLINE

11 Konotey-Ahulu FID. Opiates for sickle-cell crisis? Lancet 1998; 351(9113): 1438. May 9. PMID: 9593444 PubMed-indexed for MEDLINE

12 Konotey-Ahulu FID. Opiates for sickle-cell crisis. Lancet 1998; 352(9128): 651-652. Aug 22. PMID:9746049 PubMed-indexed to MEDLINE

13 Konotey-Ahulu FID. Opiates for pain in dying patients and in those with sickle cell disease. 11 October 2007 BMJ Rapid Response http://www.bmj.com/cgi/eletters/335/7622/685#177986

14 Konotey-Ahulu FID. Sickle Cell Disease in successive Ghanaian generations for three centuries (Manya Krobo Tribe) In The Human Genome Diversity Project: Cogitations of An African Native. Politics and the Life Sciences (PLS) 1999, Vol 18: No 2, pp 317-322. http://www.konotey- ahulu.com/images.generation.jpg

15 Konotey-Ahulu FID. The Sickle-cell Diseases: Clinical manifestations including the Sickle Crisis. Arch Inten Med 1974; 133(4): 611-619. http://archinte.ama.assn.org/cgi/reprint/133/4/611-pdf or http://archinte.ama.assn.org/cgi/content/abstract/133/4/611 [PMID: 4818434 PubMed – indexed for MEDLINE]

16 Konotey-Ahulu FID. The sickle cell disease patient: natural history from a clinico-epidemiological study of the first 1550 patients of Korle Bu Hospital Sickle Cell Clinic. Watford Tetteh-A’Domeno Company 1996 & The Macmillan Press Ltd, London 1991/1992.

17 Konotey-Ahulu FID. Publications annually from 1965 to 2009 http://www.konotey-ahulu.com/publications_annual.htm

18 Konotey-Ahulu FID. Sickle Cell Disease: The Case for Family Planning. Accra. ASTAB Books, Ltd 1973; 32 pages.

19 Ringelhann B, Konotey-Ahulu FID. Hemoglobinopathies and thalassemias in Mediterranean areas and in West Africa: Historical and other perspectives 1910 to 1997 – A Century Review. Atti dell’Accademia dell Science di Ferrara ( Milan) 1998; 74: 267-307.

20 Konotey-Ahulu FID. Need for ethnic experts to tackle genetic public health. http://www.thelancet.com/journals/lancet/article/PIIS0140- 6736(07)61771-1/fultext Lancet 2007; 370: 1836 [doi:10.1016/50140- 6736(07)61771-1]

Competing interests: None declared.

Sickle Cell Disease Patients dying from Opiates: Why no co-operation among doctors? Mawunu Chapman Nyaho

http://www.bmj.com/cgi/eletters/339/sep01_1/b3536#220670 British Medical Journal 21 September 2009

WARNINGS FROM A QUARTER OF A CENTURY AGO

WARNINGS FROM A QUARTER OF A CENTURY AGO

Ethnic minorities and sickle cell disease

British Medical Journal 20 April 1985  Volume 290, page 1214

 
SIR,-Dr John Black's article (30 March, p 984) is most helpful. Many family doctors are quite familiar with much of what he has so lucidly stated. The reason why many children (and adults) with sickle cell disease continue to die “before their time” in the UK and elsewhere is failure to appreciate certain facts relating to presentation, a failure of anticipation, and what I usually call a combination of circumstances.

First, presentation. Epistaxis, priapism, enuresis, numbness of the lower lip, sudden aphasia, hemiplegia, blood in the urine, deep jaundice, large tummy, nails white as a sheet, loud precordial murmurs, bruit de diable at the root of the neck, unexplained fever, cough with tachypnoea, fatigability, swollen hands may each and severally be the first indication that the child has sickle cell disease.' Alternatively, a child's condition may have nothing to do with sickle cell disease but may later be worsened by it-for example, within seven days lobar pneumonia can become pneumonia plus infarction plus pulmonary abscess.' Presentations may also differ from those described in the textbooks. (1) Teenagers of 12, 13, 14, or 15 years with SS disease may have spleens which, far from vanishing, are enlarged. (2) The child with genuine SS disease (parents AS, AS) with haemoglobin of 12-3 g/dl should not be treated as having sickle cell trait, because the potential for devastating in vivo sickling is there. (3) Extreme fatigability with “nails as white as a sheet” during an attack of measles indicates an aplastic crisis from the measles virus. Haemoglobin drops to 2-5 g/dl within 48 hours. As little as 100-150 ml of packed cells for a 5 year old child and not more than one unit for a 15 year old given over eight hours is lifesaving, even when the haemoglobin was less than 3 g/dl to start with.

Secondly, clinicians should anticipate disasters in patients with sickle cell disease. For example, if perioperative fluid therapy is not planned for a child about to undergo surgery the child will end up with a stroke. Anaesthetists are now more careful than ever so their success is virtually 100″,,, but fluid management before, during, and after operation often leaves a lot to be desired. The clinician should also be aware that the patient who has been admitted and discharged twice within the past week has come in again to die unless the whole management is overhauled.

Thirdly, there are many dangerous combinations of circumstances that may lead to disaster for the unwary. (1) Personnel: the houseman or GP is away for the weekend; the locum has little clue about what is happening and goes by the packed cell volume or haemoglobin concentration rather than the patient's condition; the casualty department may refuse to admit the patient, quibbling over whether the patient should go under a physician or a haematologist. (2) Clinical: abdominal pain might be due to sickle cell crisis,2 3 or the crisis could also have been precipitated by acute appendicitis.' (3) Genetic: hardly any west African with sickle cell anaemia is without one or more of the other hereditary erythrocytopathies: 86'U/ have concomitant lac or 2ac thalassaemia, and, although this is supposed to ameliorate the SS phenotype, 2OO, of the men and 16″(, of the women also have glucose-6- phosphate dehydrogenase (G6PD) deficiency.4 Contrary to what is claimed from the USA, G6PD deficiency on top of sickle cell disease is an added liability4 (Luzzato L, paper at International Symposium on Sickle Cell Anaemia, Abidjan, Ivory Coast, 1975). Workers in the UK should always identify which of their patients have G6PD deficiency, because several antimicrobial agents and analgesics which are given to help may in fact harm the patient.

FELIX KONOTEY-AHULU
London WIN IAA

1 Konotey-Ahulu FID. The sickle cell diseases. Clinical manifestations including the “sickle crisis.” Arch Intern Med 1974;133:611-19.
2 Hendrickse RG. Sickle cell anaemia in Nigerian children. Cent AfrJa Med 1960;6:45-57.
3 Valman HB. ABC of I to 7. London: British Medical journal, 1982:21.
4 Acquaye CTA, Gbedemah KA, Konotey-Ahulu FID. Glucose-6 phosphate dehydrogenase deficiency in sickle cell disease patients in Accra. Ghana Med 7 1977;16:15-8.